Alcon (ALC) Fundamentals 2026 — P/E 40.5x, Revenue Analysis | SniperIQ
Alcon (ALC) is a CH-listed Healthcare company in Medical - Specialties with a market capitalization of
Alcon's trailing twelve-month P/E ratio is 40.5x, with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Alcon runs a net profit margin of 7.7%, a gross margin of 54.9%, and an operating margin of 12.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Alcon reported revenue of
Alcon offers a trailing dividend yield of about 0.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Alcon carries a debt-to-equity ratio of 0.24x and a current ratio of 2.20x, with a market beta of 0.70. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Alcon (ALC) the key facts are: market cap
Get Alcon's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.